Recruiting soon

Beta Glucan 500 Effects on Biological and Immune Age Markers

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Beta Glucan

Dietary Supplement
Who is being recruted

Over 40 Years
See all eligibility criteria
How is the trial designed

Other Study

Phase 2
Interventional
Study Start: August 2025
See protocol details

Summary

Principal SponsorOvationLab
Study ContactChris D'Adamo Principal Investigator, PhD
Last updated: December 11, 2025
Sourced from a government-validated database.Claim as a partner
Study start date: August 1, 2025Actual date on which the first participant was enrolled.

This study is focused on understanding how a supplement called Beta Glucan 500 might affect certain biological markers that indicate a person's biological and immune age. It targets healthy adults, aiming to see if this supplement can potentially slow down or alter these age markers. This is important because it could provide insights into maintaining health and longevity by potentially modifying the body's aging process and boosting the immune system. The study involves participants taking two capsules of Beta Glucan 500 daily for 12 weeks. Researchers will use a comprehensive test panel called TruAge to measure changes in markers associated with biological and immune age. This is an open-label study, meaning all participants will know they are receiving the actual supplement, and there is no placebo group. The goal is to observe any changes in these markers over the course of the study to better understand the supplement's effects.

Official TitleProspective Human Study Evaluating the Effects of Beta Glucan 500 on Markers of Biological Age and Immune Age: An Open-label Pilot Study 
NCT07104929
Principal SponsorOvationLab
Study ContactChris D'Adamo Principal Investigator, PhD
Last updated: December 11, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
60 patients to be enrolledTotal number of participants that the clinical trial aims to recruit.
Other Study
Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.

How participants are assigned to different groups/arms
In this clinical study, all participants receive the same treatment. Since there is only one group, there is no need for randomization or assignment to different arms. This type of study is often used to test a new treatment without comparing it to another.

Other Ways to Assign Participants
Randomized allocation: Participants are assigned randomly, like flipping a coin, to ensure fairness and reduce bias.
Non-randomized allocation: Participants are assigned based on specific factors, such as their medical condition or a doctor's decision.

How treatments are given to participants
In this study, all participants receive the same treatment. This approach is often used to evaluate the effects of a single intervention without comparing it to another.

Other Ways to Assign Treatments
Parallel assignment: Participants are split into separate groups, each receiving a different treatment.
Cross-over assignment: Participants switch between treatments during the study.
Factorial assignment: Participants receive different combinations of treatments.
Sequential assignment: Participants receive treatments one after another in a specific order, possibly based on individual responses.
Other assignment: Treatment assignment does not follow a standard or predefined design.

How the effectiveness of the treatment is controlled
In a non placebo-controlled study, no participants receive an inert substance (placebo) to compare outcomes. Instead, all participants receive either the experimental treatment or an alternative treatment (often the Standard of Care). This method allows researchers to compare the effects of the experimental treatment with those of a different active intervention, rather than a placebo.

Other Options
Placebo-Controlled: A placebo is used to compare the effects of the experimental treatment with those of an inert substance, isolating the true treatment effect.

How the interventions assigned to participants is kept confidential
Everyone involved in the study knows which treatment is being given. This is typically used when it's not possible or necessary to hide the treatment details from participants or researchers.

Other Ways to Mask Information
Single-blind: Participants do not know which treatment they are receiving, but researchers do.
Double-blind: Neither participants nor researchers know which treatment is given.
Triple-blind: Participants, researchers, and outcome assessors do not know which treatment is given.
Quadruple-blind: Participants, researchers, outcome assessors, and care providers all do not know which treatment is given.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria
Any sexBiological sex of participants that are eligible to enroll.
Over 40 YearsRange of ages for which participants are eligible to join.
Healthy volunteers allowedIf individuals who are healthy and do not have the condition being studied can participate.
Criteria

Inclusion Criteria: 1. Adult females or males age ≥ 40 years 2. Ability to read and speak English 3. Previous completion of a TruDiagnostic TruAge test within the past three months to enable comparison of previous biomarkers to the same biomarkers after intervention 4. DunedinPACE estimate of aging \>0.9 Exclusion Criteria: 1. Current diagnosis and treatment for an autoimmune condition 2. Current use of beta-glucan or mushroom dietary supplement 3. Known allergies to beta glucan, yeast, or mushrooms 4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks 5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol 6. Participants unable to provide consent

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives
One single intervention group 

is designated in this study

This study does not include a placebo group 

Treatment Groups
Group I
Experimental

12 weeks of supplementation with two capsules daily of BWH Labs Beta Glucan 500
Study Objectives
Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 1 location
Suspended
OvationLabRichmond, United StatesSee the location
Recruiting soonOne Study Center
;